GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinflammatory response

Experimental Hematology

Volumn 35, Issue 8, 2007, Pages 1163-1171

  Eksioglu, Erika A ^a   Mahmood, Syed S ^a   Chang, Myron ^a   Reddy, Vijay ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11 ANTIGEN; CD123 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; LECTIN; LIPOPOLYSACCHARIDE; PHYTOHEMAGGLUTININ; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER RELAPSE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; STATISTICAL ANALYSIS; T LYMPHOCYTE;

CELL DIFFERENTIATION; CELL LINE; CYTOKINES; DENDRITIC CELLS; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFLAMMATION; INTERLEUKIN-12; KINETICS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; T-LYMPHOCYTES;

EID: 34447649892     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.05.001     Document Type: Article

References (36)

1. Cella M., Sallusto F., and Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 9 (1997) 10-16
2. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
3. Rissoan M.C., Soumelis V., Kadowaki N., et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 283 (1999) 1183-1186
4. Bottomly K. T cells and dendritic cells get intimate. Science 283 (1999) 1124-1125
5. Ardavin C., Martinez del Hoyo G., Martin P., et al. Origin and differentiation of dendritic cells. Trends Immunol 22 (2001) 691-700
6. Reddy V., Iturraspe J.A., Tzolas A.C., Meier-Kriesche H.U., Schold J., and Wingard J.R. Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease. Blood 103 (2004) 4330-4335
7. Reddy V., Winer A.G., Eksioglu E., Meier-Kriesche H.U., Schold J.D., and Wingard J.R. Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11 (2005) 1014-1021
8. Reddy V. Granulocyte colony-stimulating factor mobilization alters dendritic cell cytokine production and initiates T helper 2 polarization prior to host alloantigen presentation. Blood 96 (2000) 2635
9. Everly J.J., and Lonial S. Immunomodulatory effects of human recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF): evidence of antitumour activity. Expert Opin Biol Ther 5 (2005) 293-311
10. Timmerman J.M., and Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 50 (1999) 507-529
11. Banchereau J., and Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5 (2005) 296-306
12. Dranoff G., Jaffee E., Lazenby A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90 (1993) 3539-3543
13. Dranoff G., and Mulligan R.C. Activities of granulocyte-macrophage colony-stimulating factor revealed by gene transfer and gene knockout studies. Stem Cells 12 suppl 1 (1994) 173-182
14. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev 188 (2002) 147-154
15. Hurtado R., Candelaria M., Vargas F., Majluf A., Bolanos F., and Labardini J.R. rHuGM-CSF after high-dose chemotherapy in post-remission acute leukemia. Stem Cells 13 (1995) 112-122
16. Gluckman J.C., Canque B., Chapuis F., and Rosenzwajg M. In vitro generation of human dendritic cells and cell therapy. Cytokines Cell Mol Ther 3 (1997) 187-196
17. Zou G.M., and Tam Y.K. Cytokines in the generation and maturation of dendritic cells: recent advances. Eur Cytokine Netw 13 (2002) 186-199
18. Kiertscher S.M., Gitlitz B.J., Figlin R.A., and Roth M.D. Granulocyte/macrophage-colony stimulating factor and interleukin-4 expand and activate type-1 dendritic cells (DC1) when administered in vivo to cancer patients. Int J Cancer 107 (2003) 256-261
19. Soruri A., and Zwirner J. Dendritic cells: limited potential in immunotherapy. Int J Biochem Cell Biol 37 (2005) 241-245
20. Simons J.W., and Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol 24 (2006) 419-424
21. Hege K.M., Jooss K., and Pardoll D. GM-CSF gene-modified cancer cell immunotherapies: of mice and men. Int Rev Immunol 25 (2006) 321-352
22. Yang Y.G., Dey B., Sergio J.J., and Sykes M. Interleukin-12 prevents severe acute graft-versus-host disease (GVHD) and GVHD-associated immune dysfunction in a fully major histocompatibility complex haplotype-mismatched murine bone marrow transplantation model. Transplantation 64 (1997) 1343-1352
23. Nemunaitis J. Cytokine-mobilized peripheral blood progenitor cells. Semin Oncol 23 (1996) 9-14
24. Welte K., Gabrilove J., Bronchud M.H., Platzer E., and Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 88 (1996) 1907-1929
25. Arpinati M., Green C.L., Heimfeld S., Heuser J.E., and Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 95 (2000) 2484-2490
26. Sloand E.M., Kim S., Maciejewski J.P., et al. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 95 (2000) 2269-2274
27. Volpi I., Perruccio K., Tosti A., et al. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood 97 (2001) 2514-2521
28. Hill G.R., and Ferrara J.L. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95 (2000) 2754-2759
29. Lonial S., Hicks M., Rosenthal H., et al. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Biol Blood Marrow Transplant 10 (2004) 848-857
30. Waller E.K., and Ernstoff M.S. Modulation of antitumor immune responses by hematopoietic cytokines. Cancer 97 (2003) 1797-1809
31. Fattorossi A., Battaglia A., Pierelli L., et al. Effects of granulocyte-colony-stimulating factor and granulocyte/macrophage-colony-stimulating factor administration on T cell proliferation and phagocyte cell-surface molecules during hematopoietic reconstitution after autologous peripheral blood progenitor cell transplantation. Cancer Immunol Immunother 49 (2001) 641-648
32. Lowes M.A., Bishop G.A., Crotty K., Barnetson R.S., and Halliday G.M. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J Invest Dermatol 108 (1997) 914-919
33. Stumbles P.A., Thomas J.A., Pimm C.L., et al. Resting respiratory tract dendritic cells preferentially stimulate T helper cell type 2 (Th2) responses and require obligatory cytokine signals for induction of Th1 immunity. J Exp Med 188 (1998) 2019-2031
34. Pulendran B., Banchereau J., Maraskovsky E., and Maliszewski C. Modulating the immune response with dendritic cells and their growth factors. Trends Immunol 22 (2001) 41-47
35. Hellman P., and Eriksson H. Early activation markers of human peripheral dendritic cells. Hum Immunol 68 (2007) 324-333
36. Ebner S., Ratzinger G., Krosbacher B., et al. Production of IL-12 by human monocyte-derived dendritic cells is optimal when the stimulus is given at the onset of maturation, and is further enhanced by IL-4. J Immunol 166 (2001) 633-641